BridgeBio Pharma, Inc. (BBIO) Quick Ratio
- Quick ratio · latest quarter: Value 1.09×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.09× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $974.64M ÷ $890.65M ≈ 1.09× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 974.64M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 890.65M USD | Liabilities, Current |
| Cash and equivalents | 677.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 42.25M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 254.48M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 52.84M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $974.64M | $890.65M | $677.91M | $42.25M | $254.48M | $52.84M | 1.09× |
| 2026-03-31 | $1.15B | $816.37M | $879.89M | $60.30M | $205.23M | $32.98M | 1.40× |
| 2025-12-31 | $726.93M | $287.97M | $570.12M | $17.36M | $139.44M | $26.75M | 2.52× |
| 2025-09-30 | $762.46M | $216.60M | $642.95M | $2.99M | $116.52M | $24.53M | 3.52× |
| 2025-06-30 | $833.76M | $175.85M | $748.95M | $7.94M | $76.87M | $18.28M | 4.74× |
| 2025-03-31 | (m) | $152.10M | $540.60M | (m) | $115.27M | $3.95M | (m) |
| 2024-12-31 | (m) | $154.40M | $681.10M | (m) | $4.72M | (m) | (m) |
| 2024-09-30 | (m) | $139.22M | $266.32M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $134.36M | $407.96M | $39.81M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $141.48M | $475.22M | $44.47M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $143.84M | $375.94M | $0.00 | (m) | (m) | (m) |
| 2023-09-30 | (m) | $106.06M | $505.21M | $0.00 | (m) | (m) | (m) |
| 2023-06-30 | (m) | $110.12M | $302.44M | $30.87M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $96.60M | $407.37M | $34.12M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $121.43M | $376.69M | $51.58M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $119.19M | $483.24M | $75.08M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $141.16M | $470.10M | $218.47M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $103.46M | $371.55M | $261.90M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $135.07M | $393.77M | $393.74M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $95.82M | $180.35M | $419.26M | (m) | (m) | (m) |
| 2021-06-30 | $838.88M | $131.91M | $378.42M | $459.24M | $1.21M | (m) | 6.36× |
| 2021-03-31 | (m) | $94.73M | $471.18M | $447.94M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $95.65M | $356.08M | $251.01M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $75.71M | $366.97M | $343.71M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $92.64M | $540.92M | $300.02M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $64.91M | $757.05M | $148.13M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $60.38M | $363.77M | $182.22M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $39.86M | $413.97M | $122.08M | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $112.40M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $373.03M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $238.70M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $211.72M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $92.00M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |